ArticleBMC infectious diseases2019
Active immunoprophyilaxis with uromune® decreases the recurrence of urinary tract infections at three and six months after treatment without relevant secondary effects.
Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04173013 (Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections), which is not on this map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI)
Who cites it
31 citing papers in PubMed.
- Review
- Current Evidence on Safety, Efficacy and Efficiency of Sublingual Vaccine UromunePathogens (Basel, Switzerland) · 2025Review
- A Systematic Review of the Current Evidence of the Effectiveness and Safety of Immunoprophylaxis Using Sublingual Dead Whole Bacteria to Prevent Recurrent Urinary Tract Infections (rUTIs).Antibiotics (Basel, Switzerland) · 2025Review
- Antimicrobial resistance and vaccines in Enterobacteriaceae including extraintestinal pathogenic Escherichia coli and Klebsiella pneumoniae.npj antimicrobials and resistance · 2025Review
- Bacterial adhesion strategies and countermeasures in urinary tract infection.Nature microbiology · 2025Review
- Evaluating the use of UromuneBMC infectious diseases · 2025Article
- Reshaping Resistance: How Autovaccine Therapy Alters the Course of Recurrent Multidrug-Resistant Urinary Tract Infections.Life (Basel, Switzerland) · 2025Article
- Autovaccine immunoprophylaxis in patients with neurogenic bladder experiencing recurrent urinary tract infections.Frontiers in immunology · 2025Article
- Immunoprophylaxis with MV140 Is Effective in the Reduction of Urinary Tract Infections-A Prospective Real-Life Study.Vaccines · 2024Article
- MV140 Mucosal Vaccine Induces Targeted Immune Response for Enhanced Clearance of UropathogenicVaccines · 2024Article
- Immunoactive Prophylaxis Protocol of Uncomplicated Recurrent Urinary Tract Infections in a Cohort of 1104 Women Treated with UromuneLife (Basel, Switzerland) · 2024Article
- MV140 sublingual vaccine reduces recurrent urinary tract infection in women Results from the first North American clinical experience study.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024Article
- Autovaccine-Based Immunotherapy: A Promising Approach for Male Recurrent Urinary Tract Infections.Life (Basel, Switzerland) · 2024Article
- Hit 'em Where It Hurts: Gram-Negative Bacterial Lipopolysaccharide as a Vaccine Target.Microbiology and molecular biology reviews : MMBR · 2023Review
- Global, regional, and national estimates of the impact of a maternal Klebsiella pneumoniae vaccine: A Bayesian modeling analysis.PLoS medicine · 2023Article
- An Effective Sublingual Vaccine, MV140, Safely Reduces Risk of Recurrent Urinary Tract Infection in Women.Pathogens (Basel, Switzerland) · 2023Article
- Effects of aging on urinary tract epithelial homeostasis and immunity.Developmental biology · 2023Review
- A sublingual nanofiber vaccine to prevent urinary tract infections.Science advances · 2022Article
- Genomics and pathotypes of the many faces of Escherichia coli.FEMS microbiology reviews · 2022Article
- Sublingual Boosting with a Novel Mucoadhesive Thermogelling Hydrogel Following Parenteral CAF01 Priming as a Strategy Against Chlamydia trachomatis.Advanced healthcare materials · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo prospectively analyze the efficacy of uromune® in the prevention of uncomplicated recurrent urinary tract infections at 3 and 6 months, and according to gender and menopause.
methodsFrom September 2011 to December 2017 uromune® was administered sublingually every 24 h along 3 months to 784 patients with history of three or more uncomplicated urinary tract infections in the 12 months prior to the first visit. The variables analyzed with statistical package system for science version 15.0 were age, gender, number of urinary tract infections with positive urine culture in the first consultation, and 3 and 6 months after the end of treatment. The results with positive urine culture were registered at 3 and 6 months after the end of the treatment according to gender and also in the menopausal group with respect to pre-menopausal women.
resultsMean age was 73.5 years. 82.7% were women and 94.3% menopausal. The number of episodes of urinary tract infections in the 12 months prior to uromune® were 3 in 37.2%, 4 in 28.1%, 5 in 19.5%, 6 in 9.6%, 7 in 4%, 8 in 1.4%, 9 in 0.1% and 10 in 0.1%. Three months after uromune® 44.1% had 0 urinary tract infections and 27.6% had 1. After 6 months the results were 0 urinary tract infections in 32.3% and 1 in 32.4%. Women had 0 urinary tract infections after 3 months in 45.4% and 1 in 28.5%. At 6 months the female had 0 episodes in 32.7% and 1 in 33.2%. Menopausal women had 0 urinary tract infections at 3 months in 46.5% and 1 in 28% and at 6 months scored 0 episodes in 33.6% and 1 in 32.9%.
conclusionsUromune® was highly effective to reduce the number of episodes of urinary tract infections at three and six months of follow-up. Uromune® reduced the number of episodes to zero or one in 71.7 and 64.7% at three and six months with minimal side effects. The best results were observed in women over 50 years old. Sublingual immunoprophylaxis with uromune® could be the treatment of first choice in the prevention of uncomplicated recurrent urinary tract infections according to the sample analyzed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.